Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

BeNeLuxA Readiness Levels Vary for EU JCA…

At the European Commission's stakeholder event "From Theory to Practice: Implementing the EU Health Technology Assessment Regulation (HTAR)," held in Utrecht on January 30, 2024, representatives from the BeNeLuxA countries shared insights on their preparedness for the upcoming implementation of the EU Joint Clinical AssessmentAmong the BeNeLuxA countries, Luxembourg exhibits the lowest readiness rating of 1-3 due to its size and import reliance, while the Netherlands demonstrates the highest confidence with a readiness rating of 7. Austria rates readiness at 5 as it harmonizes fragmented systems, Ireland actively participates with a readiness rating of 7, and Belgium faces organizational challenges, rating readiness at 3All country representatives committed to utilizing the JCAs, expressing optimism; however, challenges were mentioned, including tight timelines and the early generation of PICOs (Population, Intervention, Comparison, Outcome)

NMPA's Approval of Piasky Signals Evolving Global…

The National Medical Products Administration (NMPA) of China recently approved Roche's Piasky (crovalimab), an injection for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)While Piasky has undergone worldwide development, China is the first market to approve itAlan Crowther, EVERSANA's General Manager of Global Pricing, Access and Digital Solutions, believes the approval is emblematic of two key trends: The rise of China as an early launch market, and increasingly competitive orphan and rare disease areas

European Commission Approves Casgevy

The European Commission has granted conditional marketing authorization to Vertex's Casgevy, a CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemiaCasgevy is the only gene therapy approved for both conditions in the EU and is currently also authorized in the UK, U.S., Bahrain, and Saudi ArabiaVertex believes there are over 8,000 eligible patients for Casgevy in Europe and is working with national health authorities to secure access as "quickly as possible"

'Knowledge Gaps' Persist in Rare Disease Community…

A new report from Clinigen shows that two-thirds of the rare disease community are comfortable receiving medicines before they are licensed, but a third are unaware of Early Access Programs (EAPs) that enable access to unlicensed medicinesThe NaviGATE study found that while a third of respondents had heard of EAPs, very few felt confident in navigating them. This highlights a knowledge gap that can be addressed through education and better access to informationSuzanne Aitken, SVP of Managed Access at Clinigen, suggests a number of ways patient awareness can be improved to help both understanding and uptake of these pathways, ultimately ensuring patient access to life-saving medicines that are not commercially available 

LAST WEEK IN REVIEW

Spain’s Ministry of Health could disclose the prices of certain medicines, marking a potential breakthrough in transparency in the pharmaceutical industry. The announcement comes after the advocacy of Civio, a nonprofit organization dedicated to promoting transparency in public affairs, which previously announced that Spain's Contentious-Administrative Court number 4 dismissed Novartis' appeal, to keep the pricing and financing terms negotiated for Zolgensma (onasemnogene abeparvovec) confidentialUnder a new mechanism unveiled by Chinese officials, drug companies could conduct their own quantitative evaluations, and drug prices are determined by the market, thereby creating returns that mirror high risks and high investment. The more points the drug scores in the system, the greater the freedom the company wields in its initial launch priceAccess, affordability, accountability, and ethical considerations were some of the main themes discussed at this year’s World Health Organisation’s (WHO) Fair Pricing Forum, as experts called for a greater need for transparency in drug pricing negotiations

Meet us at World EPA Congress 2024!

We are pleased to announce that NAVLIN DAILY is an official media partner with the World Evidence, Pricing, and Access (EPA) Congress, taking place March 12 to 13, 2024, at the RAI Congress Centre in AmsterdamThe congress promises valuable insights from industry experts, including value-based pricing, real-world evidence, digital health, patient engagement, and biosimilarsAs a valued EVERSANA customer, you can use our EVER50 registration discount code for a registration discount

Experts Call for Accountability & Affordability at WHO…

Access, affordability, accountability, and ethical considerations were some of the main themes discussed at this year’s World Health Organisation’s (WHO) Fair Pricing Forum, as experts called for a greater need for transparency in drug pricing negotiationsSpeaking at the event, Momir Radulovic, Head of Slovenian Medicines and Medical Devices Agency (JAZMP), stated that transparency is not an easy task to deliver, as full disclosure of documents “might not improve access”. However, Radulovic believes that transparency might help with the cost of drugs, as pharma “spending is rapidly outpacing the overall health expenditures and economic growth”Pricing transparency in drug negotiations is crucial for informed decision-making and fair market value, but experts believe it must be balanced with concerns such as stifled innovation, competitive disadvantage, complexity, confidentiality, and market distortion

Meet us at ACCESS24!

Join NAVLIN at ACCESS 2024 in Miami from 23-25 Feb 2024 to explore AI's role in revolutionizing U.S. market access for pharmaceuticalsHear from EVERSANA's General Manager, Alan Crowther, on how AI and predictive tools with NAVLIN can transform market access strategiesDiscover how NAVLIN's next-gen analytics can forecast market demand, predict launch prices, and drive faster market access penetration in oncology, CNS, rare diseases, and more

INSIGHT: Europe Waded Cautiously into Legislation…

In April 2023 the European Commission published its long-awaited proposals for the revision of the EU general pharmaceutical legislation. The document includes proposals for a new Directive and a new Regulation, which revise and replace the existing pharmaceutical legislation via the largest reform in over 20 yearsThe new “master” Regulation merges Commission Regulation No 726/2004, Orphan Medicinal Products (OMP) Regulation No 141/2000 and Paediatric Regulation No 1901/2006, and a proposal for a Directive, repealing Directive 2001/83/ECOver the course of 2023, Rapporteurs proposed amendments, the pharma industry pushed back against some of the more impactful measures and experts continually discussed the implications of the proposals. Heading into 2024, stakeholders are in a grey zone of anticipating the switch without having the tools or knowledge to take precautionary actions and optimize their ability to do exactly what the legislation claims to be about - improve patient access

Germany Introduces an Option for Confidential Rebates

Germany plans to introduce an option for confidential rebates, in order to "enhance flexibility" in negotiations between manufacturers and health insurance funds. These rebates will be at the request of the manufacturer, and will remain confidential until the eight-year regulatory data protection period expiresThe recently published Medicines Research Act (MFG) allows manufacturers to negotiate confidential rebates without considering prices in other EU countries. However, transparency is slightly maintained in the sense that the rebated prices must be disclosed to entitled parties, such as self-payers and private health insurance fundsThe introduction of confidential rebates may impact parallel trade in Germany, as drugs subject to rebates will be exempt from the requirement for pharmacies to dispense parallel imports. This could also impede parallel exports from Germany, as non-transparent prices eliminate the price differentials that drive parallel trade

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!